ADAKVEO (crizanlizumab-tmca)
MONOCLONAL ANTIBODY - SELECTIN INHIBITORS · SICKLE CELL DISEASE
Novartis Pharmaceuticals
Drug class
Monoclonal Antibody - Selectin Inhibitors
Monoclonal antibody selectin inhibitors are targeted biological agents designed to bind specific selectin cell-adhesion proteins, most notably P-selectin, expressed on activated vascular endothelium and platelets. Read more about Monoclonal Antibody - Selectin Inhibitors
2 drugs in this class 2 manufacturers
Drugs in Monoclonal Antibody - Selectin Inhibitors
ADAKVEO (crizanlizumab-tmca)
MONOCLONAL ANTIBODY - SELECTIN INHIBITORS · SICKLE CELL DISEASE
Novartis Pharmaceuticals
Filter & compare in the drug finder →
Opens the drug finder with Monoclonal Antibody - Selectin Inhibitors preselected. Add indication or manufacturer filters there.
Monoclonal antibody selectin inhibitors are targeted biological agents designed to bind specific selectin cell-adhesion proteins, most notably P-selectin, expressed on activated vascular endothelium and platelets.
By blocking the interaction between selectins and their physiological ligands, such as P-selectin glycoprotein ligand-1, these agents inhibit abnormal multicellular adhesion and aggregation among leukocytes, platelets, sickled erythrocytes, and endothelial surfaces.
Clinically, this class is primarily utilized in hematology to reduce the frequency of painful vaso-occlusive crises in patients with sickle cell disease.
-
fda.gov
Monoclonal antibody selectin inhibitors are targeted biological agents designed to bind specific selectin cell-adhesion proteins, most notably P-selectin, expressed on activated vascular endothelium and platelets By blocking the interaction between selectins and their physiological ligands, such as P-selectin glycoprotein ligand-1, these agents inhibit abnormal multicellular adhesion and aggregation among leukocytes, platelets, sickled erythrocytes, and endothelial surfaces
-
ashpublications.org
Monoclonal antibody selectin inhibitors are targeted biological agents designed to bind specific selectin cell-adhesion proteins, most notably P-selectin, expressed on activated vascular endothelium and platelets Clinically, this class is primarily utilized in hematology to reduce the frequency of painful vaso-occlusive crises in patients with sickle cell disease
-
nih.gov
By blocking the interaction between selectins and their physiological ligands, such as P-selectin glycoprotein ligand-1, these agents inhibit abnormal multicellular adhesion and aggregation among leukocytes, platelets, sickled erythrocytes, and endothelial surfaces Clinically, this class is primarily utilized in hematology to reduce the frequency of painful vaso-occlusive crises in patients with sickle cell disease
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.